BMS enters two immuno-oncology deals
Bristol-Myers Squibb has deepened its bets on immuno-oncology. The drugmaker announced Tuesday that it is testing its experimental PD-1 inhibitor nivolumab in combination with Incyte's oral dioscygenase-1 inhibitor, INCB24360.
The Phase I/II study will address multiple tumor types, which the companies said in a joint statement may include melanoma, non-small cell lung cancer, ovarian cancer and squamous cell carcinoma of the head and neck, among others.
BMS announced in April that it planned to complete its nivolumab rolling submission to the FDA for non-small cell lung cancer at the end of this year.
Tuesday's collaboration news also included Bristol Myers-Squibb's announcement that it was taking up with CytomX Therapeutics to develop “novel therapies against multiple immuno-oncology targets using CytomX's proprietary Probody Platform.” The companies explained in a joint statement that probodies are selectively activated antibodies which can spare healthy tissue.
The includes a $50 million upfront payment to CytomX and gives BMS exclusive rights to develop probodies for up to four oncology targets.